Skip to main content

Table 3 Efficacy

From: Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer

  Phase 1b Phase 2a
Total (N = 60) Group A (n = 22) Group B (n = 22) All (N = 44)
Best overall response,a n (%)     
 Complete response 1 (2) 1 (4.8)b 1 (4.5) 2 (4.7)c
 Partial response 34 (57) 13 (61.9)b 15 (68.2) 28 (65.1)c
 Stable disease 22 (37) 6 (28.6)b 5 (22.7) 11 (25.6)c
 Progressive disease 3 (5) 1 (4.8)b 1 (4.5) 2 (4.7)c
Clinical benefit rated     
 n (%) 40 (66.7) 12 (54.5) 13 (59.1) 25 (56.8)
 95 % CI 53.5 − 78.3 32.7 − 74.0 38.3 − 79.3 41.6 − 71.0
No. of patients with measurable disease n = 55 n = 21 n = 21 n = 42
Objective response ratee     
 n (%) 30 (54.5) 10 (47.6) 11 (52.4) 21 (50.0)
 95 % CI 40.6 − 68.0 27.6 − 70.2 29.8 − 72.4 34.6 − 65.4
  1. CI confidence interval
  2. aAt any time point with responses ordered complete response > partial response > stable disease > progressive disease
  3. bOf 21 patients with best response
  4. cOf 43 patients with best response
  5. dIncludes patients with complete response, partial response, or stable disease of ≥6 months duration, as assessed by the investigator
  6. eIncludes only those patients with confirmed complete and partial responses, and is calculated based on patients with measurable disease